Literature DB >> 21570912

Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Michelle A Rudek1, Charles Flexner, Richard F Ambinder.   

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21570912      PMCID： PMC3343721          DOI： 10.1016/S1470-2045(11)70056-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


  109 in total

1.  Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

Authors:  V A Eagling; D J Back; M G Barry
Journal:  Br J Clin Pharmacol       Date:  1997-08       Impact factor: 4.335

2.  Drugs and the QT interval - caveat doctor.

Authors:  Barbara A Liu; David N Juurlink
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

3.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

4.  In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9.

Authors:  R Singh; S Y Chang; L C Taylor
Journal:  Rapid Commun Mass Spectrom       Date:  1996       Impact factor: 2.419

5.  Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.

Authors:  S K Balani; E J Woolf; V L Hoagland; M G Sturgill; P J Deutsch; K C Yeh; J H Lin
Journal:  Drug Metab Dispos       Date:  1996-12       Impact factor: 3.922

6.  Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.

Authors:  Gondi N Kumar; Venkata K Jayanti; Marianne K Johnson; John Uchic; Samuel Thomas; Ronald D Lee; Brian A Grabowski; Hing L Sham; Dale J Kempf; Jon F Denissen; Kennan C Marsh; Eugene Sun; Stanley A Roberts
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

7.  Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.

Authors:  Niresh Hariparsad; Srikanth C Nallani; Rucha S Sane; Donna J Buckley; Arthur R Buckley; Pankaj B Desai
Journal:  J Clin Pharmacol       Date:  2004-11       Impact factor: 3.126

8.  Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes.

Authors:  Srikanth C Nallani; Bryan Goodwin; Arthur R Buckley; Donna J Buckley; Pankaj B Desai
Journal:  Cancer Chemother Pharmacol       Date:  2004-06-03       Impact factor: 3.333

9.  Predicting etoposide toxicity: relationship to organ function and protein binding.

Authors:  S P Joel; R Shah; P I Clark; M L Slevin
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

10.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

Authors:  G N Kumar; A D Rodrigues; A M Buko; J F Denissen
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030
View more
  40 in total

1.  Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Authors:  Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-09-19       Impact factor: 4.335

2.  A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.

Authors:  Ramesh Rengan; Rosemarie Mick; Daniel Pryma; Mark A Rosen; Lilie L Lin; Amit M Maity; Tracey L Evans; James P Stevenson; Corey J Langer; John Kucharczuk; Joseph Friedberg; Susan Prendergast; Tiffany Sharkoski; Stephen M Hahn
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

3.  Cancer treatment disparities in HIV-infected individuals in the United States.

Authors:  Gita Suneja; Meredith S Shiels; Rory Angulo; Glenn E Copeland; Lou Gonsalves; Anne M Hakenewerth; Kathryn E Macomber; Sharon K Melville; Eric A Engels
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

Review 4.  Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.

Authors:  Paul G Rubinstein; David M Aboulafia; Andrew Zloza
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

5.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

6.  Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer.

Authors:  Sukhwant N Singh; Yue Zhu; Saranya Chumsri; Susan Kesmodel; Bruce L Gilliam; David J Riedel
Journal:  Clin Breast Cancer       Date:  2013-11-20       Impact factor: 3.225

7.  Pharmacotherapy in cancer patients with HIV/AIDS.

Authors:  J H Beumer; R Venkataramanan; M A Rudek
Journal:  Clin Pharmacol Ther       Date:  2014-01-17       Impact factor: 6.875

8.  Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Authors:  J Chen; V Mehraj; J Szabo; B Routy; R P Michel; J P Routy
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 9.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

Review 10.  Human immunodeficiency virus-associated lung malignancies.

Authors:  Allison A Lambert; Christian A Merlo; Gregory D Kirk
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.